Contact us

Our latest news

Back to news >

Pharmaceutical Analysis: New UHPLC enhances our offering

Seda’s latest acquisition – a shiny new UHPLC (Agilent 1290 Infinity II) expanding our capabilities in pharmaceutical analysis and enabling rapid and reliable data generation for Clients.

The 1290 Infinity II LC System is an ultra-high performance liquid chromatography instrument (UHPLC)  designed to be both a HPLC and high-end UHPLC system in a single flow path.

Our extensive analytical capabilities and suite of in-house analytical instrumentation allow us to support a range of CMC activities extending from early phase method development stability studies and impurity analysis, through to excipient compatibility studies and understanding product formulation and behaviour. The increasing complexity of pharmaceutical compounds encountered today requires a deep understanding of analytical techniques which we apply to solve the most challenging of problems.

Seda’s laboratories can be used as a standalone service which delivers the ‘nuts and bolts’ of data generation. Alternatively, it can be combined with our drug product consulting service to provide the additional advantage of seamless integration of the experimental plan with top end Strategy, Interpretation and Execution which can maximise value build and speed of development.

  • Our laboratory services include:
  • Physicochemical characterisation and preformulation services
  • Pharmaceutical analysis
  • Analytical method development and verification
  • Chemical and physical stability studies
  • Preclinical efficacy and safety study formulation development (with a special focus on challenging molecules)
  • First-in-Human formulation prototyping
  • Pharmaceutical development activities
  • Later phase / commercial formulation prototyping
  • Biorelevant dissolution and development of clinically relevant dissolution tests
  • Enabling formulations and specialist drug delivery technology selection

Find out more about the laboratory services we can offer.